N. Bone

发表

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.

T. Shanafelt, N. Kay, D. Jelinek, 2008, Leukemia research.

in chronic lymphocytic leukemia B cells B target genes and induction of apoptosis κ silencing of nuclear factor Inhibition of glycogen synthase kinase-3 activity leads to epigenetic

N. Kay, M. Fernández-Zapico, A. Ougolkov, 2011 .

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.

N. Kay, M. Fernández-Zapico, A. Ougolkov, 2007, Blood.

Correction: potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis

D. Mukhopadhyay, Lichun Lu, M. Yaszemski, 2013, Journal of Nanobiotechnology.

A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.

R. Puri, D. Frank, N. Kay, 2005, Leukemia research.

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

T. Shanafelt, N. Kay, D. Jelinek, 2010, Leukemia.

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.

M. Grever, J. Byrd, T. Shanafelt, 2006, Leukemia research.

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

T. Shanafelt, G. Dewald, S. Geyer, 2008, British journal of haematology.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male

A. Dalmasso, N. Kay, M. Hupke, 1990 .

Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male.

A. Dalmasso, N. Kay, M. Hupke, 1990, Blood.

Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NFkB Nuclear Activity.

N. Kay, A. Ougolkov, D. Billadeau, 2006 .

Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine.

E. Sausville, T. Shanafelt, S. Kaufmann, 2004, Blood.

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, J. Hoyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human T-cell function in experimental ascorbic acid deficiency and spontaneous scurvy 13

N. Kay, N. Bone, W. Duane, 2005 .

Inhibition of GSK-3 Activity Leads to Epigenetic Silencing of NF κ B Target Genes and Induction of Apoptosis in CLL B-Cells

N. Kay, M. Fernández-Zapico, A. Ougolkov, 2007 .

Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.

N. Kay, M. Fernández-Zapico, A. Ougolkov, 2007, Blood.

Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.

I. Ghobrial, S. Ansell, N. Kay, 2004, Mayo Clinic proceedings.

Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis

Michael J Yaszemski, Chitta Ranjan Patra, Lichun Lu, 2007, Journal of nanobiotechnology.

Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B‐CLL patients: impact on clonal B‐cell apoptosis

N. Kay, N. Bone, Gary J. Williams, 2001, British journal of haematology.

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B‐cell chronic lymphocytic leukaemia

J. O'fallon, G. Dewald, N. Kay, 2003, British journal of haematology.

Analysis of clonal B‐cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B‐chronic lymphocytic leukaemia

A. Tefferi, G. Dewald, S. Geyer, 2001, British journal of haematology.

Lymphocytic Leukemia Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a

N. Kay, D. Jelinek, N. Bone, 2013 .

chronic lymphocytic leukemia green tea component, epigallocatechin-3-gallate (EGCG), in B-cell VEGF receptor phosphorylation status and apoptosis is modulated by a

T. Shanafelt, N. Kay, D. Jelinek, 2011 .

VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia.

T. Shanafelt, N. Kay, D. Jelinek, 2004, Blood.

Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.

M. Oken, R. Kyle, P. Greipp, 1997, Blood.

Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.

B. Ness, M. Oken, R. Kyle, 2001, Blood.

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance

T. Shanafelt, N. Kay, D. Jelinek, 2005, Leukemia.

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

E. Sausville, D. Loegering, J. Karp, 2003, Blood.

Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

T. Shanafelt, J. Katzmann, R. Clark, 2007, Translational research : the journal of laboratory and clinical medicine.

Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

T. Shanafelt, N. Kay, A. Raza, 2007, Leukemia research.

Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487).

M. Oken, R. Kyle, P. Greipp, 1999, Leukemia and Lymphoma.

Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.

L. Rassenti, T. Kipps, T. Shanafelt, 2005 .

Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.

M. Grever, J. Byrd, G. Dewald, 2004 .

Human T-cell function in experimental ascorbic acid deficiency and spontaneous scurvy.

N. Kay, N. Bone, W. Duane, 1982, The American journal of clinical nutrition.

multiple myeloma patients an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed Blood levels of immune cells predict survival in myeloma patients: results of

B. Ness, M. Oken, R. Kyle, 2013 .

T‐helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93

M. Oken, N. Kay, B. V. Van Ness, 1998, British journal of haematology.

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia.

T. Shanafelt, G. Dewald, J. Hoyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.